Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.

In a preceding study in which single-agent matuzumab (800, 1200, and 1600 mg) was administered on a weekly basis, highly significant changes in pEGFR, pMAPK, Ki-67, and p27 kip1 expression were seen in skin biopsies obtained at day 28, but no quantitative differences were apparent among the three dose groups ( Vanhoefer et al , 2004 ) with respect to any of these markers, and complete abrogation of pEGFR, pMAPK, and Ki-67 expression was not achieved even with the highest doses.

also in 132,142 other papers